Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
473 questions in 36 reviews · HIV/AIDS
current versionsNo studies 38 · 8%Ungraded 9 · 1.9%Very low 126 · 26.6%Low 127 · 26.8%Moderate 152 · 32.1%High 21 · 4.4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intervention NR Ever diarrhea history · patients with HIV infection or exposure Prevention of diarrhoea in children with HIV infection or exposure to maternal HIV infection (2010) · Cochrane | RR 1.33 [0.98, 1.81] | 1 study · 363 participants | Very low |
Intervention NR Adverse events Grade 3 or 4 adverse event · patients with HIV infection or exposure Prevention of diarrhoea in children with HIV infection or exposure to maternal HIV infection (2010) · Cochrane | RR 0.9 [0.47, 1.73] | 1 study · 534 participants | Low |
Intervention NR Hospitalisations due to diarrhoea · patients with HIV infection or exposure Prevention of diarrhoea in children with HIV infection or exposure to maternal HIV infection (2010) · Cochrane | RR 1.55 [0.86, 2.79] | 1 study · 534 participants | Low |
Intervention NR Respiratory infections hospital admission for pneumonia/empyema · patients with HIV infection or exposure Prevention of diarrhoea in children with HIV infection or exposure to maternal HIV infection (2010) · Cochrane | RR 0.84 [0.57, 1.24] | 1 study · 534 participants | Low |
Intervention NR Hospitalisations for diarrhoea number of episodes per number · patients with diarrhoea in children with HIV infection Prevention of diarrhoea in children with HIV infection or exposure to maternal HIV infection (2010) · Cochrane | RR 0.25 [0.05, 1.15] | 1 study · 194 participants | Low |
Intervention NR Incidence acute diarrhoea different measures by history · patients with diarrhoea in children with HIV infection Prevention of diarrhoea in children with HIV infection or exposure to maternal HIV infection (2010) · Cochrane | no estimate extracted | 3 studies · 267 participants | Very low |
Intervention NR Incidence persistent diarrhoea · patients with diarrhoea in children with HIV infection Prevention of diarrhoea in children with HIV infection or exposure to maternal HIV infection (2010) · Cochrane | no estimate extracted | 2 studies · 209 participants | Low |
Intervention NR Severity diarrhoea by history and or physical exam · patients with diarrhoea in children with HIV infection Prevention of diarrhoea in children with HIV infection or exposure to maternal HIV infection (2010) · Cochrane | no estimate extracted | 2 studies · 239 participants | Very low |
Intervention NR Respiratory infections history and/or physical exam · patients with diarrhoea in children with HIV infection Prevention of diarrhoea in children with HIV infection or exposure to maternal HIV infection (2010) · Cochrane | no estimate extracted | 3 studies · 267 participants | Low |
Intervention NR Mortality, all‐cause · patients with HIV exposure (children) Prevention of diarrhoea in children with HIV infection or exposure to maternal HIV infection (2010) · Cochrane | no estimate extracted | 2 studies · 2966 participants | Low |
Intervention NR Mortality, diarrhoea‐specific ‐ not reported · patients with HIV exposure (children) Prevention of diarrhoea in children with HIV infection or exposure to maternal HIV infection (2010) · Cochrane | no estimate extracted | NR | No studies |
d4T vs AZT Mortality · patients with initial treatment of HIV infection in antiretroviral‐naive individuals Stavudine or zidovudine in three‐drug combination therapy for initial treatment of HIV infection in… (2010) · Cochrane | RR 1.36 [0.34, 5.42] | 6 studies · 1179 participants | Very low |
d4T vs AZT Clinical progression · patients with initial treatment of HIV infection in antiretroviral‐naive individuals Stavudine or zidovudine in three‐drug combination therapy for initial treatment of HIV infection in… (2010) · Cochrane | RR 0.78 [0.28, 2.13] | 7 studies · 719 participants | Low |
d4T vs AZT Severe adverse events · patients with initial treatment of HIV infection in antiretroviral‐naive individuals Stavudine or zidovudine in three‐drug combination therapy for initial treatment of HIV infection in… (2010) · Cochrane | RR 1.17 [0.97, 1.4] | 9 studies · 1363 participants | Low |
d4T vs AZT Virologic response · patients with initial treatment of HIV infection in antiretroviral‐naive individuals Stavudine or zidovudine in three‐drug combination therapy for initial treatment of HIV infection in… (2010) · Cochrane | RR 1.03 [0.88, 1.19] | 12 studies · 2157 participants | Low |
d4T vs AZT Adherence/tolerability/retention · patients with initial treatment of HIV infection in antiretroviral‐naive individuals Stavudine or zidovudine in three‐drug combination therapy for initial treatment of HIV infection in… (2010) · Cochrane | RR 0.94 [0.84, 1.05] | 12 studies · 2157 participants | Low |
d4T vs AZT Immunologic response · patients with initial treatment of HIV infection in antiretroviral‐naive individuals Stavudine or zidovudine in three‐drug combination therapy for initial treatment of HIV infection in… (2010) · Cochrane | no estimate extracted | 10 studies · 1537 participants | Low |
d4T vs AZT Drug resistance · patients with initial treatment of HIV infection in antiretroviral‐naive individuals Stavudine or zidovudine in three‐drug combination therapy for initial treatment of HIV infection in… (2010) · Cochrane | RR 0.66 [0.25, 1.73] | 1 study · 174 participants | Very low |
TDF vs AZT Serious adverse events · patients with initial ART Tenofovir or zidovudine in three‐drug combination therapy with one nucleoside reverse transcriptase… (2010) · Cochrane | RR 0.92 [0.6, 1.43] | 2 studies · 586 participants | High |
TDF vs AZT Virologic response · patients with initial ART Tenofovir or zidovudine in three‐drug combination therapy with one nucleoside reverse transcriptase… (2010) · Cochrane | RR 2.04 [0.17, 24.84] | 2 studies · 586 participants | High |
TDF vs AZT Adherence/tolerability/retention · patients with initial ART Tenofovir or zidovudine in three‐drug combination therapy with one nucleoside reverse transcriptase… (2010) · Cochrane | RR 1.17 [1.06, 1.29] | 2 studies · 586 participants | Moderate |
TDF vs AZT Immunological response · patients with initial ART Tenofovir or zidovudine in three‐drug combination therapy with one nucleoside reverse transcriptase… (2010) · Cochrane | no estimate extracted | 1 study · 515 participants | Moderate |
TDF vs AZT Drug resistance · patients with initial ART Tenofovir or zidovudine in three‐drug combination therapy with one nucleoside reverse transcriptase… (2010) · Cochrane | RR 20.43 [1.24, 335.9] | 1 study · 71 participants | Very low |